Genmab receives orphan drug designation from FDA
The US Health authority has granted orphan drug status to Genmab’s lymphoma treatment, epcoritamab, which is being developed alongside Abbvie.
by marketwire, translated by daniel pedersen
Danish biotech company Genmab announces in a press release that the US Food and Drug Administration (FDA) has designated the company’s investigational drug, epcoritamab, an orphan drug.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Abbvie seeks to add major depressive disorder to drug label
For subscribers
